NASDAQ:OBIO Orchestra BioMed (OBIO) Stock Price, News & Analysis $3.24 -1.04 (-24.30%) Closing price 04:00 PM EasternExtended Trading$3.24 0.00 (0.00%) As of 07:35 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Orchestra BioMed Stock (NASDAQ:OBIO) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Orchestra BioMed alerts:Sign Up Key Stats Today's Range$3.17▼$4.0650-Day Range$3.24▼$5.9852-Week Range$3.22▼$8.87Volume188,260 shsAverage Volume84,415 shsMarket Capitalization$123.17 millionP/E RatioN/ADividend YieldN/APrice Target$15.40Consensus RatingBuy Company OverviewOrchestra BioMed Holdings, Inc. operates as a biomedical innovation company. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension (HTN); and Virtue Sirolimus AngioInfusion Balloon (SAB) for the treatment of atherosclerotic artery disease. Its products also comprise FreeHold devices and minimally invasive surgery devices. The company has a collaboration agreement with Medtronic, Inc. for the development and commercialization of BackBeat CNT for the treatment of HTN in patients indicated for a cardiac pacemaker; and a strategic collaboration with Terumo Medical Corporation for the development and commercialization of Virtue SAB for the treatment of coronary and peripheral artery disease. Orchestra BioMed Holdings, Inc. is based in New Hope, Pennsylvania.Read More… Remove Ads Orchestra BioMed Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks34th Percentile Overall ScoreOBIO MarketRank™: Orchestra BioMed scored higher than 34% of companies evaluated by MarketBeat, and ranked 698th out of 930 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingOrchestra BioMed has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageOrchestra BioMed has only been the subject of 3 research reports in the past 90 days.Read more about Orchestra BioMed's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Orchestra BioMed are expected to decrease in the coming year, from ($1.66) to ($1.95) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Orchestra BioMed is -2.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Orchestra BioMed is -2.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioOrchestra BioMed has a P/B Ratio of 1.71. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Orchestra BioMed's valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted2.04% of the float of Orchestra BioMed has been sold short.Short Interest Ratio / Days to CoverOrchestra BioMed has a short interest ratio ("days to cover") of 5.8.Change versus previous monthShort interest in Orchestra BioMed has recently increased by 4.08%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldOrchestra BioMed does not currently pay a dividend.Dividend GrowthOrchestra BioMed does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted2.04% of the float of Orchestra BioMed has been sold short.Short Interest Ratio / Days to CoverOrchestra BioMed has a short interest ratio ("days to cover") of 5.8.Change versus previous monthShort interest in Orchestra BioMed has recently increased by 4.08%, indicating that investor sentiment is decreasing. News and Social Media2.4 / 5News Sentiment0.27 News SentimentOrchestra BioMed has a news sentiment score of 0.27. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.78 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Orchestra BioMed this week, compared to 1 article on an average week.MarketBeat Follows1 people have added Orchestra BioMed to their MarketBeat watchlist in the last 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Orchestra BioMed insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 6.70% of the stock of Orchestra BioMed is held by insiders.Percentage Held by Institutions53.55% of the stock of Orchestra BioMed is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Orchestra BioMed's insider trading history. Receive OBIO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Orchestra BioMed and its competitors with MarketBeat's FREE daily newsletter. Email Address OBIO Stock News HeadlinesOrchestra BioMed Reports Full Year 2024 Financial Results and Provides a Fourth Quarter Business UpdateMarch 31 at 4:21 PM | globenewswire.comOrchestra BioMed (NASDAQ:OBIO) Earns Buy Rating from Analysts at BTIG ResearchMarch 22, 2025 | americanbankingnews.comTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to move your money now.April 1, 2025 | Porter & Company (Ad)Orchestra BioMed initiated with a Buy at BTIGMarch 21, 2025 | markets.businessinsider.comBTIG Initiates Coverage of Orchestra BioMed Holdings (OBIO) with Buy RecommendationMarch 21, 2025 | msn.comOrchestra BioMed to Present at Upcoming Investor ConferencesFebruary 20, 2025 | globenewswire.comOrchestra names Vivek Reddy as chairman of BACKBEAT study steering committeeFebruary 19, 2025 | markets.businessinsider.comOrchestra BioMed Appoints Vivek Reddy, M.D. as Executive Chairman of the BACKBEAT Study Steering Committee and Chairman of Bioelectronic Therapies Scientific Advisory BoardFebruary 18, 2025 | globenewswire.comSee More Headlines OBIO Stock Analysis - Frequently Asked Questions How have OBIO shares performed this year? Orchestra BioMed's stock was trading at $4.00 at the beginning of the year. Since then, OBIO shares have decreased by 19.0% and is now trading at $3.24. View the best growth stocks for 2025 here. How were Orchestra BioMed's earnings last quarter? Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) issued its quarterly earnings results on Wednesday, April, 2nd. The company reported ($0.43) EPS for the quarter, hitting the consensus estimate of ($0.43). The firm had revenue of $0.25 million for the quarter, compared to the consensus estimate of $0.79 million. Orchestra BioMed had a negative trailing twelve-month return on equity of 107.04% and a negative net margin of 2,179.33%. How do I buy shares of Orchestra BioMed? Shares of OBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Orchestra BioMed own? Based on aggregate information from My MarketBeat watchlists, some other companies that Orchestra BioMed investors own include Tesla (TSLA), JPMorgan Chase & Co. (JPM), Meta Platforms (META), Advanced Micro Devices (AMD), NVIDIA (NVDA), Netflix (NFLX) and Home Depot (HD). Company Calendar Today4/01/2025Last Earnings4/02/2025Next Earnings (Estimated)4/02/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryMedical Equipment Current SymbolNASDAQ:OBIO CIK1814114 Weborchestrabiomed.com Phone646-597-6980FaxN/AEmployees4Year FoundedN/APrice Target and Rating Average Stock Price Target$15.40 High Stock Price Target$20.00 Low Stock Price Target$12.00 Potential Upside/Downside+375.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($1.61) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-49,120,000.00 Net Margins-2,179.33% Pretax Margin-2,179.33% Return on Equity-107.04% Return on Assets-70.88% Debt Debt-to-Equity RatioN/A Current Ratio4.23 Quick Ratio4.21 Sales & Book Value Annual Sales$2.65 million Price / Sales46.53 Cash FlowN/A Price / Cash FlowN/A Book Value$1.90 per share Price / Book1.71Miscellaneous Outstanding Shares38,014,000Free Float35,467,000Market Cap$123.17 million OptionableNot Optionable Beta0.59 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report This page (NASDAQ:OBIO) was last updated on 4/1/2025 by MarketBeat.com Staff From Our PartnersA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredTrump Allies Confirm Exec Order 14024 Triggers Dollar CollapseExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredTrump’s Secret WeaponHave you looked at the stock market recently? Millions of investors are scrambling trying to figure out what's...American Alternative | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsMusk confirmed that SpaceX's Starship will carry Optimus to Mars in 2026 as part of an autonomous mission to h...InvestorPlace | SponsoredRetirement Nightmare? It’s Already Happening.The market is on edge. Every day, another company slashes its dividend, leaving investors scrambling. Intel...Investors Alley | SponsoredNew “Trump” currency proposed in DCA former U.S. Presidential Advisor has come forward with a stern warning to investors: “Get out of tech, no...Paradigm Press | SponsoredBrace Yourself for Jeff Bezos’ “Amazon Helios”Jeff Bezos quietly backing world-changing tech (not AI) The Amazon founder is quietly advancing a radical t...Stansberry Research | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Orchestra BioMed Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Orchestra BioMed With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.